ENGLISH
CBS2017
Previous Next
Home < 科学研究

搜索结果

数量：1763 条

排序

Refine search

Angiotensin–neprilysin inhibition versus enalapril in heart failure

Clinical Trial | By McMurray JJ, Packer M, PARADIGM-HF Investigators and Committees.

Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure

Clinical Trial | By McMurray JJ, Krum H, ATMOSPHERE Committees Investigators.

Cardiac Troponin Elevation in Patients Without a Specific Diagnosis

Original Research | By KM Eggers, T Jernberg, B Lindahl.

BACKGROUND - Cardiac troponin (cTn) elevation is a common finding in acutely admitted patients, even in the absence of acute coronary syndrome. In some of these patients, no etiology of cTn elevation can be identified. The term troponinemia is sometimes used to describe this scenario.   OBJECTIVES - This study aimed to investigate the associations of cTn levels with clinical findings and long-term outcome in ...

Clinical Outcome After DK Crush Versus Culotte Stenting of Distal Left Main Bifurcation Lesions: The 3-Year Follow-Up Results of the DKCRUSH-III Study

Clinical Trial | By Chen SL, Xu B, Han YL et al.

A randomized clinical study comparing double kissing crush with provisional stenting for treatment of coronary bifurcation lesions: results from the DKCRUSH-II (Double Kissing Crush versus Provisional Stenting Technique for Treatment of Coronary Bifurcation Lesions) trial

Clinical Trial | By Chen SL, Santoso T, Zhang JJ et al.

Contemporary techniques in percutaneous coronary intervention for bifurcation lesions

Review Article | By Collet C, Mizukami T, Grundeken MJ.

Treatment of coronary bifurcation lesions with contemporary state-of-the-art percutaneous coronary intervention (PCI) is still associated with higher rate of adverse cardiovascular events compared to non-bifurcation lesions. Bench testing and virtual computer modeling have increased our understanding of bifurcation PCI guiding refinement in bifurcation techniques. New insights on bifurcation PCI have the potential to further improve clinical outcomes in...

Effect of Medication Co-payment Vouchers on P2Y12 Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction: The ARTEMIS Randomized Clinical Trial

Clinical Trial | By Wang TY, Kaltenbach LA, Cannon CP et al.

IMPORTANCE - Despite guideline recommendations, many patients discontinue P2Y12 inhibitor therapy earlier than the recommended 1 year after myocardial infarction (MI), and higher-potency P2Y12 inhibitors are underutilized. Cost is frequently cited as an explanation for both of these observations. OBJECTIVE - To determine whether removing co-payment barriers increases P2Y12 inhibitor persistence and lo...

Incidence, predictors, and outcomes of DAPT disruption due to non-compliance vs. bleeding after PCI: insights from the PARIS Registry

Clinical Trial | By Moalem K, Baber U, Mehran R et al.

BACKGROUND - The disruption of dual antiplatelet therapy (DAPT) due to non-compliance or bleeding is known to significantly increase the risk of adverse outcomes after percutaneous coronary intervention (PCI). However, it is currently unknown if there are differences in the predictors and clinical impact of disruption due to non-compliance compared with bleeding.   METHODS - The patterns of non-adherence t...

Switching P2Y12-receptor inhibitors in patients with coronary artery disease

Review Article | By Rollini F, Franchi F, Angiolillo DJ.

Dual antiplatelet therapy--the combination of aspirin and a P2Y12-receptor inhibitor--is the cornerstone of treatment of patients with acute coronary syndromes (ACS) and of those undergoing percutaneous coronary intervention. Prasugrel and ticagrelor have more prompt, potent, and predictable antiplatelet effects than those of clopidogrel, and result in reduced ischaemic outcomes in patients with ACS, albeit at the expense of an ...

Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial

Clinical Trial | By Valgimigli M, Frigoli E, MATRIX Investigators.

BACKGROUND - The Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox (MATRIX) programme was designed to assess the comparative safety and effectiveness of radial versus femoral access and of bivalirudin versus unfractionated heparin with optional glycoprotein IIb/IIIa inhibitors in patients with the whole spectrum of acute coronary syndrome undergoing invasive manage...

By Article Type

Original Research 785
Review Article 294
Clinical Case Study 28
Clinical Trial 415
Perspective 9
Guideline 50

By Year

2019 3
2018 2
2016 2
2015 1
2014 1
2011 1

By Journal

Nat Rev Cardiol. 1
N Engl J Med. 2
Lancet. 1
JAMA. 1
JACC Cardiovasc Interv. 1
J Am Coll Cardiol. 1
J Am Coll Cardiol. 1
Expert Rev Cardiovasc Ther. 1
Clin Res Cardiol. 1

Limit By

Title
Content
|<<... 67 68 69 70 71 72 73 ...>>|
↑BACK TO TOP

左主干暨冠状动脉分叉病变峰会

南京市心血管医院丨南京市第一医院丨南京医科大学

长乐路68号丨210006丨中国 · 南京

Copyright ⓒ CBSMD Nanjing China. All rights reserved.

关于境内代表注册有疑问请联系彭红娟、徐海梅老师

+86 - 139 138 954 77 丨 +86 - 139 147 368 46 丨 cbsnj@cbsmd.org

关于境外代表注册有疑问请联系林玲老师

+86 - 139 518 845 96 丨 cbsnj@cbsmd.org

关于学术征集有疑问请联系赵莹莹女士

+86 138 154 085 17 丨 sub@cbsmd.org